2. Autophagy
  3. Autophagy
  4. PHY34

PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer.

For research use only. We do not sell to patients.

PHY34 Chemical Structure

PHY34 Chemical Structure

CAS No. : 2130033-55-3

Size Price Stock Quantity
1 mg In-stock
5 mg   Get quote  
10 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

PHY34 Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

PHY34 is an inhibitor that inhibits ATP6V0A2 and CAS thereby inhibiting autophagy, and has a nanomolar effect. PHY34 inhibits cancer cell growth by inducing apoptosis and inhibits tumor growth in xenograft models. PHY34 can be used for research on high grade serous ovarian cancer[1][2].

IC50 & Target

ATP6V0A2, cellular apoptosis susceptibility (CAS)[2]
In Vitro

PHY34 (0.001 nM-50 μM, 72 h) inhibits various cancer cells growth with nanomolar potency through activation of apoptosis based on enhanced cPARP levels and has the highest potency in HGSOC cell lines[1].
PHY34 (100 nM, 1 μM; 24 h) blocks the final breakdown of the autolysosomes in OVCAR8 at 100 nM, and in OVCAR3 at 1 μM, respectively[1].
PHY34 (10 nM, 24 h) inhibits the late-stage autophagy that precedes apoptosis induction in OVCAR8[1].
PHY34 (100 nM, 48 h) inhibits the late-stage autophagy that precedes apoptosis induction in OVCAR3[1].
PHY34 (0.01 nM-2 μM, 72 h) induces cell death in the presence of wild-type V0A2, but not V823I mutants in H4 cell[2].
PHY34 (10, 100 nM; 48 h, 72 h) changes subcellular localization of nuclear multiple proteins[2].
PHY34 (20 μM, 1 h) binds specificity with ATP6V0A2 subunit[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PHY34 Related Antibodies

Cell Viability Assay[1][2]

Cell Line: OVCAR8, OVCAR3, HT-29, MDA-MB-435, MDA-MB-231, IOSE80, FT33
Concentration: 0.001 nM-50 μM
Incubation Time: 72 h
Result: Inhibited the growth of various cancer cells with IC50 values of 4 nM(OVCAR8, OVCAR3), 43.3 nM(HT-29) , 23 nM(MDA-MB-435) , 5.2 nM(MDA-MB-231).
Exhibited no toxicity to IOSE80 and FT33 (IC50 >50 μM).

Cell Viability Assay[2]

Cell Line: H4
Concentration: 0.01 nM-2 μM
Incubation Time: 72 h
Result: Inhibited mutant cell with an IC50 value of 246 pM that was 1000-fold more potent than HTP-013(434 nM).
Conferred resistance in V8231 mutation and no impact activity in T216A mutation.

Apoptosis Analysis[1]

Cell Line: OVCAR8, OVCAR3
Concentration: 10 nM, 100 nM
Incubation Time: 72 h
Result: Increased the number of cells in early and late apoptosis in OVCAR8 and OVCAR3 at 10 nM and 100 nM, respectively.

Cell Autophagy Assay[1]

Cell Line: Hela
Concentration: 9.31 fM-20 μM
Incubation Time: 4 h
Result: Sustained high levels of LC3B puncta with an EC50 value of 2 nM.
Inhibited autophagy with an EC50 value of 3.9 nM.

Cell Autophagy Assay[2]

Cell Line: OVCAR3
Concentration: 5 nM
Incubation Time: 4 h
Result: Inhibited autophagy with an ED50 value of 6.29 nM, and was more potent than bafilomycin A1 (HY-100558) with an ED50 value of 29.1 nM.

Western Blot Analysis[1][2]

Cell Line: OVCAR8, OVCAR3, OVCAR4
Concentration: 10 nM, 100 nM
Incubation Time: 48 h, 72 h
Result: Increased cPARP levels in OVCAR8 after 48 h at 10 nM, in OVCAR4 and OVCAR3 after 72 h at 100 nM, respectively.
Reversed the conversion of PARP to cPARP combined with RAP (HY-10219) of 1 μM.

Western Blot Analysis[2]

Cell Line: OVCAR8, OVCAR3, OVCAR4
Concentration: 10 nM
Incubation Time: 24 h, 48 h, 72 h
Result: Promoted histone H3, LAMP1/2, ACSS2, and PCNA nuclear protein accumulation at 48 h.
Reduced expression of KPNA2 (Karyopherin subunit alpha 2) with time-dependent manner.
Increased nuclear accumulation of mutant p53 at 48 h.
In Vivo

PHY34 (0.75 mg/kg, i.p., 3 times a week for 3 weeks) inhibits tumor growth and reduces Ki67 expression in tumor tissue in a female nude mouse tumor bearing model constructed by OVCAR8[1].

PHY34 Pharmacokinetics[1]

药代动力学分析[1]

Parameter Units IV IP PO
Dose mg/kg 0.6 1.8 75
Dose nmol 1029.9 3089.8 128742.1
T1/2 hr 6.2 8.4 12.3
Tmax hr 0.08 0.25 0.25
Cmax nmol/L 288.8 519.5 323.6
AUClast hr*nmol/L 198.8 360.5 599.9
AUCinf hr*nmol/L 215.8 366.5 663.3
Vz L/kg 42.7 101.6 3430.3
CI L/hr/kg 4.8 8.4 194.1
MRT hr 6.1 1.9 7.8
F* % - 56.6 2.5

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: OVCAR8-induced xenograft models in female nude mice[1].
Dosage: 0.75 mg/kg, three times a week for three weeks
Administration: Intraperitoneal injection (i.p.)
Result: Decreased tumor burden based on average abdominal radiant efficiency with no gross toxicity through analysis of fluorescence imaging.
Molecular Weight

582.55

Formula

C30H30O12
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C1C2=C(C3=CC=C(OCO4)C4=C3)C5=CC(OC)=C(OC)C=C5C(O[C@H]6[C@@H]([C@]7([H])[C@](OC(C)(O7)C)([H])[C@H](O6)CO)O)=C2CO1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (171.66 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.7166 mL 8.5830 mL 17.1659 mL
5 mM 0.3433 mL 1.7166 mL 3.4332 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    90% Corn Oil

    Solubility: ≥ 2.5 mg/mL (4.29 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.7166 mL 8.5830 mL 17.1659 mL 42.9148 mL
5 mM 0.3433 mL 1.7166 mL 3.4332 mL 8.5830 mL
10 mM 0.1717 mL 0.8583 mL 1.7166 mL 4.2915 mL
15 mM 0.1144 mL 0.5722 mL 1.1444 mL 2.8610 mL
20 mM 0.0858 mL 0.4291 mL 0.8583 mL 2.1457 mL
25 mM 0.0687 mL 0.3433 mL 0.6866 mL 1.7166 mL
30 mM 0.0572 mL 0.2861 mL 0.5722 mL 1.4305 mL
40 mM 0.0429 mL 0.2146 mL 0.4291 mL 1.0729 mL
50 mM 0.0343 mL 0.1717 mL 0.3433 mL 0.8583 mL
60 mM 0.0286 mL 0.1430 mL 0.2861 mL 0.7152 mL
80 mM 0.0215 mL 0.1073 mL 0.2146 mL 0.5364 mL
100 mM 0.0172 mL 0.0858 mL 0.1717 mL 0.4291 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

PHY34 Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

PHY342130033-55-3PHY 34PHY-34AutophagyOVCAR8OVCAR3HT-29MDA-MB-435MDA-MB-231IOSE80Helaxenograft model high grade serous ovarian cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
PHY34
Cat. No.:
HY-122650
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.